FluoGuide’s proprietary uPAR-targeted luminescent technology platform makes fluorescent molecules bind to the invasive forefront of solid cancers, creating a clear delineation of cancer cells during surgery.

New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

New exchange: Nasdaq First North

Phototermal treatment

Besides providing visual guidance to surgeons, FluoGuide’s technology platform may also be utilized for photothermal treatment. Photothermal therapy is a cancer treatment that induces cancer cell death by heat generated in tumor tissue exposed to near-infrared light. FluoGuide’s FG001 has the potential to act as a near-infrared light absorbent to facilitate efficient and cancer cell targeted heat destruction.

Photothermal therapy is an extension of photodynamic therapy, in which a photosensitizer, e.g., FluoGuide’s FG001, is excited with light of a specific wavelength. This light excitation brings FG001 to an excitation state where it releases energy in the form of heat. Under optimal conditions, the generated heat will kill cancer cells while sparing normal tissue. FluoGuide started testing photothermal therapy in preclinical models in 2021.